Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Pulmonary alveolar proteinosis Indication Strategy Report 2026: GM-CSF, Trials and Deals
23 July 2026
2026 Pulmonary alveolar proteinosis strategy: epidemiology, GM-CSF biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Lymphangioleiomyomatosis Indication Strategy Report 2026: mTOR, Trials and Deals
23 July 2026
2026 Lymphangioleiomyomatosis strategy: epidemiology, mTOR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Non-cystic fibrosis bronchiectasis Indication Strategy Report 2026: DPP1, Trials and Deals
23 July 2026
2026 Non-cystic fibrosis bronchiectasis strategy: epidemiology, DPP1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Radiation enteritis Indication Strategy Report 2026: TGF-beta, Trials and Deals
23 July 2026
2026 Radiation enteritis strategy: epidemiology, TGF-beta biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pouchitis Indication Strategy Report 2026: IL-23, Trials and Deals
23 July 2026
2026 Pouchitis strategy: epidemiology, IL-23 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with PatSnap…
Latest Hotspot
8 min read
Intestinal failure Indication Strategy Report 2026: GLP-2 receptor, Trials and Deals
23 July 2026
2026 Intestinal failure strategy: epidemiology, GLP-2 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Eosinophilic colitis Indication Strategy Report 2026: IL-5, Trials and Deals
23 July 2026
2026 Eosinophilic colitis strategy: epidemiology, IL-5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Hirschsprung disease Indication Strategy Report 2026: RET, Trials and Deals
23 July 2026
2026 Hirschsprung disease strategy: epidemiology, RET biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Chronic intestinal pseudo-obstruction Indication Strategy Report 2026: 5-HT4 receptor, Trials and Deals
23 July 2026
2026 Chronic intestinal pseudo-obstruction strategy: epidemiology, 5-HT4 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Bile acid diarrhea Indication Strategy Report 2026: FXR, Trials and Deals
23 July 2026
2026 Bile acid diarrhea strategy: epidemiology, FXR biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Gastroparesis Indication Strategy Report 2026: Ghrelin receptor, Trials and Deals
23 July 2026
2026 Gastroparesis strategy: epidemiology, Ghrelin receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cyclic vomiting syndrome Indication Strategy Report 2026: NK1 receptor, Trials and Deals
23 July 2026
2026 Cyclic vomiting syndrome strategy: epidemiology, NK1 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.